# RoosterBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/roosterbio

- Industry: Biotechnology
- Headquarters: Frederick, US
- Website: www.roosterbio.com
- Total disclosed funding: $22M
- Latest round: Series B (Sep 11, 2019)
- Investors on record: 3

## About

RoosterBio, Inc., based in the US, specializes in the development and commercialization of adult human mesenchymal stem/stromal cells and supporting products for therapeutic technologies.RoosterBio, Inc. focuses on providing adult human mesenchymal stem/stromal cells (hMSCs) and related products. Founded in 2013 in Frederick, US, the company has completed 6 deals, with its most recent funding round being a Series B in September 2019, raising USD 6.50 mn led by Dynamk Capital. The company was founded by Jon Rowley, who has a background in cell therapy and regenerative medicine, and is currently led by CEO Margot Connor.RoosterBio’s primary offerings include adult human mesenchymal stem/stromal cells (hMSCs) and associated bioprocess media aimed at enhancing therapeutic technology commercialization. Their products, which derive from various tissues such as bone marrow, adipose tissue, and umbilical cord, come with advanced media for efficient cell expansion and exosome production, catering to clients in over 25 countries across six continents. Their solutions support applications in regenerative medicine, tissue engineering, and cellular therapies, providing high-quality materials and streamlined protocols for rapid product development.The company generates revenue through a business-to-business (B2B) model, primarily from sales of hMSC systems, bioprocess media, and related services. Their flagship offerings, such as QuickShip™, facilitate tailored orders for specific tissue types, enhancing procurement efficiency. The pricing is contingent upon product specifications and volumes, with products compliant with cGMP regulations, allowing clients to obtain clinically relevant quantities promptly. RoosterBio also offers process development services aligned with regulatory standards, supporting their financial model by providing comprehensive solutions for clients.Following its Series B funding round in September 2019, which raised USD 6.50 mn as part of a larger USD 21.50 mn deal led by Dynamk Capital, RoosterBio plans to invest in the development of new products aimed at expanding their product offerings in regenerative medicine. The company is also set to strategically enter new markets, focusing on expansion into Europe and Asia by 2022. The funding will facilitate these initiatives, allowing RoosterBio to enhance its research capabilities and accelerate the commercialization of its innovative solutions.

## Funding rounds

- Series B, Sep 11, 2019, $6.5M — Vanedge Capital, Planetary Technologies, Dynamk Capital
- Series B, Aug 6, 2019, $15M — Dynamk Capital

## Investors

- Dynamk Capital (https://capitalatlas.ai/funds/dynamk-capital) — Series B
- Vanedge Capital (https://capitalatlas.ai/funds/vanedge-capital) — Series B
- Planetary Technologies (https://capitalatlas.ai/funds/planetary-technologies) — Series B